Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities
Open Access
- 26 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 31 (7), 1647-1652
- https://doi.org/10.1007/s10096-011-1488-3
Abstract
To determine the profiles of susceptibility to antifungal and the genotypes of clinical isolates of Cryptococcus in Bahia, Brazil, 62 isolates were collected from cases of meningitis in the period from 2006 to 2010. Their susceptibilities to fluconazole, itraconazole, amphotericin B and 5-flucytosine were determined by the broth microdilution technique described by the Clinical and Laboratory Standards Institute and genotyping of the URA5 gene was accomplished by restriction fragment length polymorphism. C. neoformans accounted for 79% of the identified yeast and C. gattii represented the remaining 21%. Evaluation of the genotypes determined that 100% of the C. gattii isolates belong to the VGII genotype, and 98% of the C. neoformans isolates belong to the VNI genotype. Determination of susceptibility revealed isolates resistant to fluconazole (4.8%), 5-flucytosine (1.6%) and amphotericin B (3.2%); the stratification of sensitivity results for each species showed significant differences in susceptibility to azoles. This study is the first to describe the susceptibility profiles of molecular and clinical isolates of Cryptococcus in Bahia, Brazil. The high percentage of C. gattii isolates belonging to the VGII genotype and its lower susceptibility to antifungal agents highlight the importance of knowing which species are involved in cryptococcal infections in northeastern Brazil.Keywords
This publication has 48 references indexed in Scilit:
- Risk Factors forCryptococcus gattiiInfection, British Columbia, CanadaEmerging Infectious Diseases, 2011
- Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of KoreaFEMS Yeast Research, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Molecular Evidence That the Range of the Vancouver Island Outbreak ofCryptococcus gattiiInfection Has Expanded into the Pacific Northwest in the United StatesThe Journal of Infectious Diseases, 2009
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion TestingJournal of Clinical Microbiology, 2009
- Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2009
- Suscetibilidade a antifúngicos de variedades de Cryptococcus neoformans isoladas de pacientes em hospital universitárioRevista da Sociedade Brasileira de Medicina Tropical, 2008
- Molecular epidemiology ofCryptococcusneoformansisolates from AIDS patients of the Brazilian city, Rio de JaneiroMedical Mycology, 2004
- Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do SulFEMS Yeast Research, 2003